| Registry of Asthma Characterization and Recruitment 3 (RACR3) (NCT05272241) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-05-06 |
| Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents (NCT05347771) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-05-04 |
| A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes. (NCT04840199) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-04-19 |
| COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial) (NCT05289037) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-03-30 |
| Safety and Immunogenicity of an Epstein-Barr Virus (EBV) gp350-Ferritin Nanoparticle Vaccine in Healthy Adults (NCT04645147) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-03-29 |
| Phase I Norovirus Challenge Model (NCT04174560) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-03-28 |
| A Phase 1 Trial to Evaluate CAP256V2LS in Healthy Adults (NCT04408963) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-03-22 |
| Anti-malaria MAb in Malian Children (NCT05304611) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-03-18 |
| Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age (NCT04520659) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-03-16 |
| Community Dynamics of Malaria Transmission in Humans and Mosquitoes at Maferinyah Sub-Prefecture, Guinea (NCT04969913) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-03-07 |
| Evaluating the Safety and Immunogenicity of a Prime-boost Vaccine Regimen of GEO-D02 DNA and MVA/HIV62B With and Without B63521^11 gp120 and IHV01 gp120 Env Proteins in Healthy, HIV-uninfected Adult Participants (NCT04041674) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-03-01 |
| Human Immune Response to Ixodes Scapularis Tick Bites (NCT05036707) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-02-28 |
| Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND) (NCT04394884) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-02-17 |
| Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM) (NCT05123222) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-02-16 |
| Blood-Stage Plasmodium Vivax Cell Bank (NCT05095272) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-02-15 |
| A Clinical Trial to Evaluate the Safety and Immunogenicity of BG505 MD39.3, BG505 MD39.3 gp151, and BG505 MD39.3 gp151 CD4KO HIV Trimer mRNA Vaccines in Healthy, HIV-uninfected Adult Participants (NCT05217641) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-02-11 |
| An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge (NCT05048875) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-02-03 |
| Selective CD28 Blockade in Renal Transplant Recipients (NCT04903054) | National Institute of Allergy and Infectious Diseases (NIAID) | 2022-01-10 |
| Carfilzomib and Belatacept for Desensitization (NCT05017545) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-12-28 |
| COVID Protection After Transplant-Immunosuppression Reduction (NCT05077254) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-12-06 |
| Natural History, Epidemiology and Pathogenesis of Severe HPV-Related Diseases (Neptune) (NCT05026138) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-11-17 |
| Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency (NCT05078879) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-11-16 |
| A Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult Participants (NCT05184452) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-11-15 |
| Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study (NCT04311502) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-11-05 |
| Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) (NCT05099965) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-11-02 |
| Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination (NCT04722003) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-11-01 |
| Daratumumab and Belatacept for Desensitization (NCT04827979) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-11-01 |
| Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali (NCT05135273) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-10-22 |
| Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD) (NCT04918147) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-10-13 |
| Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases (NCT05078905) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-10-13 |
| Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia (NCT04704674) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-09-30 |
| Defining the COVID-19 Immunity Denominator in the Mekong: a Cross-Sectional Seroprevalence Study of SARS-CoV-2 in HealthyVolunteers (NCT04594395) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-09-24 |
| Natural History of Systemic and Nasal Mucosal Immunity After Influenza Vaccination in a Pediatric Population (NCT04963166) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-09-24 |
| PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) (NCT05780541) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-09-15 |
| Trial to Evaluate L9LS in Healthy Adults (NCT05019729) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-09-13 |
| Assess the Safety and Immunogenicity of One or Two Doses of Sing2016 M2SR H3N2 Influenza Vaccine (NCT04960397) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-09-10 |
| The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose (NCT04977479) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-09-08 |
| Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum (NCT04518228) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-09-01 |
| Vaccination for Recovered Inpatients With COVID-19 (VATICO) (NCT04969250) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-08-25 |
| Influenza Challenge Study to Determine the Optimal Infection Dose and Safety of a Recombinant H3N2 (A/Texas/71/2017 (H3N2, Clade 3C3a) Influenza Strain (NCT04978454) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-08-19 |
| Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination (NCT04794829) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-08-19 |
| International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE) (NCT05096091) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-08-16 |
| COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders (NCT05000216) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-08-13 |
| Metabolic Profiling of Immune Responses in Immune-mediated Diseases (NCT04864886) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-08-10 |
| COVID-19 Protection After Transplant Pilot Study (NCT04969263) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-08-10 |
| ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19 (NCT04988035) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-08-03 |
| PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia (NCT04926922) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-07-27 |
| SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine (NCT04952402) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-07-09 |
| Molecular Basis of Erythrocyte Invasion by Plasmodium Vivax Into Duffy-Negative Erythrocytes in Mali (NCT03304691) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-06-30 |
| Elemental Diet for Treatment of Inflammatory Bowel Disease in Patients With Chronic Granulomatous Disease (NCT03983837) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-06-23 |
| MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) (NCT05780463) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-06-11 |
| Malaria Transmission in Humans and Mosquitoes at the Area of Sabou, Burkina Faso (NCT04650815) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-06-10 |
| The Effect of Helminth Infection Plus COVID-19 Infection on the Immune Response and Intestinal Microorganisms (NCT04813328) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-06-01 |
| Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines (NCT04889209) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-05-28 |
| First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults (NCT04896086) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-05-24 |
| Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption (NCT04340596) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-05-21 |
| DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia (NCT04775953) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-04-22 |
| Liver Transplantation With Tregs at UCSF (NCT03654040) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-04-22 |
| COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations (NCT04852276) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-04-20 |
| Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial) (NCT06729593) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-04-20 |
| Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial) (NCT06729606) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-04-20 |
| ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19 (NCT04843761) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-04-20 |
| The Influence of Malnutrition, Diabetes Mellitus, and Helminth Infections on Biosignatures in Latent Tuberculosis in a South Indian Population (NCT04526613) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-04-19 |
| SARS-COV2 Pandemic Serosurvey in a Rare Disease Population (NCT04609085) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-04-19 |
| COVID-19 and Anti-CD14 Treatment Trial (NCT04391309) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-04-12 |
| COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations (NCT04761822) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-04-07 |
| Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults (NCT04785144) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-03-31 |
| PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the US (NCT04582266) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-03-31 |
| Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults (NCT04776317) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-03-25 |
| A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine (NCT04811664) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-03-24 |
| Systems Biology of Early Atopy (NCT04798079) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-03-18 |
| A Study to Assess the Safety and Immune Response to Env-C DNA and Protein Vaccines in Kenya (NCT04826094) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-03-15 |
| Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals (NCT04272242) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-02-27 |
| Study of Semaglutide for Non-Alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome With Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk (The SLIM LIVER Study) (NCT04216589) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-02-19 |
| Safety and Efficacy of CIS43LS Anti-malaria mAb in Mali (NCT04329104) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-02-15 |
| AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) (NCT05780437) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-02-10 |
| Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and Cambodia (NCT04434846) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-02-08 |
| Mepolizumab in Episodic Angioedema With Eosinophilia (NCT04128371) | National Institute of Allergy and Infectious Diseases (NIAID) | 2021-01-14 |
| Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection (NCT04350138) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-12-29 |
| VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) (NCT05780281) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-12-16 |
| BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) (NCT05780424) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-12-16 |
| B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B (NCT04193189) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-12-14 |
| Evaluation of AMG 714 for Vitiligo (NCT04338581) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-12-11 |
| Prevalence and Incidence of Lassa Virus Infection in Southern Mali (NCT03783143) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-12-04 |
| Adaptive COVID-19 Treatment Trial 4 (ACTT-4) (NCT04640168) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-12-02 |
| COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C (NCT04588363) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-11-19 |
| Sample Collection for Systems Evaluation of Patients With Unknown or Incompletely Characterized Immune Defects (NCT04408950) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-11-12 |
| Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants (NCT04212091) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-11-10 |
| Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction (NCT04502966) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-11-05 |
| Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females (NCT04824131) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-11-04 |
| A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin (NCT03891901) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-10-27 |
| Characterization of Skin Immunity to Aedes Aegypti Saliva in Dengue-endemic Participants in Cambodia (NCT04350905) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-10-27 |
| ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19 (NCT04583969) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-10-23 |
| ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19 (NCT04583956) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-10-23 |
| Phase 1 Study of SAR440894 vs Placebo (NCT04441905) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-10-14 |
| Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence (NCT04582903) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-10-13 |
| Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults (NCT04579250) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-10-08 |
| Safety and Pharmacokinetics of VT-1598 (NCT04208321) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-09-29 |
| Safety and Drug Detection Study of Dapivirine Vaginal Ring and Oral TRUVADA® in Breastfeeding Mother-Infant Pairs (NCT04140266) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-09-24 |
| The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age (NCT03760458) | National Institute of Allergy and Infectious Diseases (NIAID) | 2020-09-09 |